"Vindesine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
| Descriptor ID |
D014751
|
| MeSH Number(s) |
D03.132.436.681.827.830 D03.633.100.473.402.681.827.830
|
| Concept/Terms |
Vindesine- Vindesine
- Vindesin
- Desacetylvinblastine Amide
|
Below are MeSH descriptors whose meaning is more general than "Vindesine".
Below are MeSH descriptors whose meaning is more specific than "Vindesine".
This graph shows the total number of publications written about "Vindesine" by people in this website by year, and whether "Vindesine" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Vindesine" by people in Profiles.
-
Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chemother Pharmacol. 1992; 29(6):445-9.
-
Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989 Jul; 96(1):110-3.
-
Protochemotherapy in non-small cell lung carcinoma. An attempt to increase surgical resectability and survival. A preliminary report. Cancer. 1986 Jan 01; 57(1):44-53.
-
The impact of combined therapeutic modalities in head, neck, and esophageal cancer. Semin Surg Oncol. 1985; 1(3):116-31.
-
Trial of vindesine, etoposide, and cisplatin in patients with previously treated, advanced-stage, non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1984 Feb; 68(2):413-5.
-
Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Semin Oncol. 1983 Mar; 10(1):111-22.